114 related articles for article (PubMed ID: 10518658)
1. Design of polymeric prodrugs of prostaglandin E(1) having galactose residue for hepatocyte targeting.
Hashida M; Akamatsu K; Nishikawa M; Yamashita F; Takakura Y
J Control Release; 1999 Nov; 62(1-2):253-62. PubMed ID: 10518658
[TBL] [Abstract][Full Text] [Related]
2. Design of polymeric prodrugs of PGE1 for cell-specific hepatic targeting.
Hashida M; Akamatsu K; Nishikawa M; Yamashita F; Yoshikawa H; Takakura Y
Pharmazie; 2000 Mar; 55(3):202-5. PubMed ID: 10756541
[TBL] [Abstract][Full Text] [Related]
3. Development of a hepatocyte-specific prostaglandin E(1) polymeric prodrug and its potential for preventing carbon tetrachloride-induced fulminant hepatitis in mice.
Akamatsu K; Yamasaki Y; Nishikawa M; Takakura Y; Hashida M
J Pharmacol Exp Ther; 1999 Sep; 290(3):1242-9. PubMed ID: 10454500
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and pharmacological activity of a novel water-soluble hepatocyte-specific polymeric prodrug of prostaglandin E(1) using lactosylated poly(L-glutamic hydrazide) as a carrier.
Akamatsu K; Yamasaki Y; Nishikawa M; Takakura Y; Hashida M
Biochem Pharmacol; 2001 Dec; 62(11):1531-6. PubMed ID: 11728389
[TBL] [Abstract][Full Text] [Related]
5. Disposition characteristics of glycosylated poly(amino acids) as liver cell-specific drug carrier.
Akamatsu K; Imai M; Yamasaki Y; Nishikawa M; Takakura Y; Hashida M
J Drug Target; 1998; 6(3):229-39. PubMed ID: 9888309
[TBL] [Abstract][Full Text] [Related]
6. Influence of formulation parameters on the characteristics of poly(D, L-lactide-co-glycolide) microspheres containing poly(L-lysine) complexed plasmid DNA.
Capan Y; Woo BH; Gebrekidan S; Ahmed S; DeLuca PP
J Control Release; 1999 Aug; 60(2-3):279-86. PubMed ID: 10425333
[TBL] [Abstract][Full Text] [Related]
7. Effect of additives on gelation and tissue adhesion of gelatin-poly(L-glutamic acid) mixture.
Otani Y; Tabata Y; Ikada Y
Biomaterials; 1998 Dec; 19(23):2167-73. PubMed ID: 9884057
[TBL] [Abstract][Full Text] [Related]
8. Formulation and evaluation of tacrolimus-loaded galactosylated Poly(lactic-co-glycolic acid) nanoparticles for liver targeting.
Mistry NP; Desai JL; Thakkar HP
J Pharm Pharmacol; 2015 Oct; 67(10):1337-48. PubMed ID: 25944126
[TBL] [Abstract][Full Text] [Related]
9. Novel polymer-DNA hybrid polymeric micelles composed of hydrophobic poly(D,L-lactic-co-glycolic acid) and hydrophilic oligonucleotides.
Jeong JH; Park TG
Bioconjug Chem; 2001; 12(6):917-23. PubMed ID: 11716682
[TBL] [Abstract][Full Text] [Related]
10. Development and pharmacokinetics of galactosylated poly-L-glutamic acid as a biodegradable carrier for liver-specific drug delivery.
Hirabayashi H; Nishikawa M; Takakura Y; Hashida M
Pharm Res; 1996 Jun; 13(6):880-4. PubMed ID: 8792426
[TBL] [Abstract][Full Text] [Related]
11. Surface immobilization of galactose onto aliphatic biodegradable polymers for hepatocyte culture.
Yoon JJ; Nam YS; Kim JH; Park TG
Biotechnol Bioeng; 2002 Apr; 78(1):1-10. PubMed ID: 11857274
[TBL] [Abstract][Full Text] [Related]
12. Targeted delivery of prostaglandin E1 to hepatocytes using galactosylated liposomes.
Kawakami S; Munakata C; Fumoto S; Yamashita F; Hashida M
J Drug Target; 2000; 8(3):137-42. PubMed ID: 10938523
[TBL] [Abstract][Full Text] [Related]
13. Targeted delivery of plasmid DNA complexed with galactosylated poly(L-lysine).
Hashida M; Takemura S; Nishikawa M; Takakura Y
J Control Release; 1998 Apr; 53(1-3):301-10. PubMed ID: 9741938
[TBL] [Abstract][Full Text] [Related]
14. Physicochemical and disposition characteristics of antisense oligonucleotides complexed with glycosylated poly(L-lysine).
Mahato RI; Takemura S; Akamatsu K; Nishikawa M; Takakura Y; Hashida M
Biochem Pharmacol; 1997 Mar; 53(6):887-95. PubMed ID: 9113108
[TBL] [Abstract][Full Text] [Related]
15. Biodistribution characteristics of galactosylated emulsions and incorporated probucol for hepatocyte-selective targeting of lipophilic drugs in mice.
Ishida E; Managit C; Kawakami S; Nishikawa M; Yamashita F; Hashida M
Pharm Res; 2004 Jun; 21(6):932-9. PubMed ID: 15212156
[TBL] [Abstract][Full Text] [Related]
16. Targeted delivery of plasmid DNA to hepatocytes in vivo: optimization of the pharmacokinetics of plasmid DNA/galactosylated poly(L-lysine) complexes by controlling their physicochemical properties.
Nishikawa M; Takemura S; Takakura Y; Hashida M
J Pharmacol Exp Ther; 1998 Oct; 287(1):408-15. PubMed ID: 9765363
[TBL] [Abstract][Full Text] [Related]
17. Local sustained release of prostaglandin E1 induces neovascularization in murine hindlimb ischemia.
Esaki J; Sakaguchi H; Marui A; Bir SC; Arai Y; Huang Y; Tsubota H; Kanaji T; Ikeda T; Sakata R
Circ J; 2009 Jul; 73(7):1330-6. PubMed ID: 19436117
[TBL] [Abstract][Full Text] [Related]
18. Conjugation of drug to poly(D,L-lactic-co-glycolic acid) for controlled release from biodegradable microspheres.
Oh JE; Nam YS; Lee KH; Park TG
J Control Release; 1999 Feb; 57(3):269-80. PubMed ID: 9895414
[TBL] [Abstract][Full Text] [Related]
19. Promising galactose-decorated biodegradable poloxamer 188-PLGA diblock copolymer nanoparticles of resibufogenin for enhancing liver cancer therapy.
Dong H; Tian L; Gao M; Xu H; Zhang C; Lv L; Zhang J; Wang C; Tian Y; Ma X
Drug Deliv; 2017 Nov; 24(1):1302-1316. PubMed ID: 28895767
[TBL] [Abstract][Full Text] [Related]
20. Biodegradable nanoparticles containing doxorubicin-PLGA conjugate for sustained release.
Yoo HS; Oh JE; Lee KH; Park TG
Pharm Res; 1999 Jul; 16(7):1114-8. PubMed ID: 10450940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
